skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Etanercept in the treatment of plaque psoriasis

Review

(3781) Views  (888) Full article downloads

Authors: Thao U Nguyen, John Koo

Published Date May 2009 Volume 2009:2 Pages 77 - 84
DOI: http://dx.doi.org/10.2147/CCID.S3412

Thao U Nguyen, John Koo

Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, California, USA

Abstract: Etanercept is approved for the treatment of moderate to severe plaque psoriasis at a dose of 50 mg twice weekly for 3 months followed by a maintenance dosage of 50 mg weekly thereafter. Clinical studies have shown excellent efficacy, favorable benefit to side-effects ratio, and safe long-term usage. Extensive information on safety is available as etanercept has been used for many years for other indications such as rheumatoid arthritis and psoriatic arthritis and is the first of the tumor necrosis factor antagonists to gain approval in psoriasis.

Keywords: etanercept, plaque psoriasis, tumor necrosis factor antagonist








Readers of this article also read:
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • American Acne and Rosacea Society

    The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.